### **Overview** **Beta Drugs Limited (BDL)** is a rapidly growing, oncology-focused Indian pharmaceutical company with expanding presence in **cosmeceuticals** and **CDMO (Contract Development and Manufacturing Organization)** services. Recognized as one of the **top 10 oncology companies in India**, Beta has established strong credibility among prescribers for providing **high-quality, affordable cancer therapeutics**. The company operates through three wholly-owned subsidiaries: *Adley Formulations Pvt Ltd*, *Adley Lab Limited*, and *Beta Research Private Limited*. Backed by strategic investments and a robust vertically integrated model—from API to finished dosage form—Beta is executing a focused growth strategy to become a **global leader in cytotoxic and specialty oncology products** while scaling its presence in emerging markets and new therapeutic areas. --- ### **Core Business Segments & Market Position** #### **1. Oncology (Core Business)** - **Portfolio:** Offers **135+ oncology SKUs**, with flagship brands ranking in the **top 5 in their respective categories**. - **Market Presence:** Products available in **over 85% of government and corporate hospitals** in India. - **Branded Sales:** Domestic own-brand sales surpassed ₹100 crores in FY25, achieving 25.28% YoY growth; driven by **NDDS** and **supportive care** launches. - **Sales Mix:** Oral therapies account for **48% of branded sales**, reflecting a strategic shift from injectables toward sustainable, prescription-led oral oncology products. #### **2. Cosmeceuticals – Inspira Division** - **Division:** Rebranded as **Inspira**, targeting **dermatology and medical aesthetics** with doctor-prescribed, premium products. - **Growth:** Achieved **₹1 crore monthly revenue** by May 2024, growing to **45% YoY growth in H1 FY26**. - **Profitability:** Became **profitable in November 2025**, with EBITDA improving from ₹4 crores loss to profitability in FY25. - **Prescriber Base:** Expanded from 700 (Nov 2024) to over **2,600 dermatologists** by May 2025, with **1,500+ reached as of Nov 2025**. - **Key Products:** - *Meso-Fills*: In-licensing from Italian partner; **first registered mesotherapy product in India** (vs. unregistered Korean imports). - *Dermal fillers* and *vitamin-based mesotherapy*, targeting a **Rs 1,000 crore market**. - First-to-market launches via **European partnership**, with exclusive India rights. - **Target Market Share:** 10–20% in high-end aesthetic dermatology, which could grow to a **₹450–500 crore vertical** long-term. #### **3. CDMO (Contract Manufacturing)** - **Clients:** Serves top Indian pharma companies including **Glenmark, Intas, Alkem, Cadila, Torrent, Hetero, and MSN**. - **Specialization:** One of India’s leading **cytotoxic CDMOs**, with capabilities in *solid, liquid, injectable, lyophilized, and suspension formulations*. - **Recent Growth:** CDMO sales grew by **8% YoY**, supported by expanded capacity at **Adley Formulation** plant. - **Facility Milestone:** Launched the **world’s first cytotoxic suspension manufacturing facility in Asia**, producing *Megestrol Acetate* (branded as **Caxfila OS**). --- ### **Strategic Growth Pillars** #### **1. Backward Integration & Manufacturing Excellence** - **API Self-Sufficiency:** Produces **70% of APIs in-house**, significantly reducing dependence on Chinese suppliers. - **Recent Acquisition:** Acquired a **dedicated oncology intermediate manufacturing plant**, enabling **full control from KSM (Key Starting Material) to API**, with future CDMO potential. - **In-House Facilities:** - **Adley Lab Limited (Derabassi):** API and intermediate production, passed **COFEPRIS** and **PICS** audits. - **Beta Drugs Plant (Baddi):** Now dedicated to **export formulations**. - **Adley Formulation:** Focuses on **domestic market supply**. - **Facility Upgrades:** Upgrading for **EU-GMP compliance**; plant slated for **EU audit by Q1 FY26 (Jan–Mar 2026)**. #### **2. Innovation in R&D & Product Development** - **R&D Model:** Focuses on: - **Novel Drug Delivery Systems (NDDS)** – with multiple products already commercialized. - **Non-infringing synthetic routes** for off-patent molecules. - **Follow-on Fixed Dose Combinations (FFTL)** and **Oral Cytotoxics (NIBs, TKIs)**. - **Pipeline Highlights:** - **NDDS-Based Methotrexate Oral Solution:** First DCGI approval in India; first patient-friendly liquid alternative to tablets/injections for **oncology and autoimmune** (e.g., RA, psoriasis). - **2–3 First-to-Market Products:** In development, including first-ever **NDDS formulations in oncology** (launching FY26). - **R&D Investment:** ~2% of revenue; expanding team and infrastructure. A **new state-of-the-art R&D center** under construction to support complex molecule development. #### **3. Expanding Domestic & International Footprint** - **Domestic Focus:** Strengthening reach in **tier 2 and tier 3 cities**; adding over 200 new prescribers annually. - **International Markets:** Present in **46+ countries**, with active filings in **268 markets**. - **LatAm:** Strong presence in **Colombia (INVIMA)**, **Mexico (COFEPRIS)**, **Brazil (ANVISA)**, **Central America**, and **Paraguay, Jordan, Algeria**. - **Asia/Africa:** Exports to **Philippines, Thailand, Vietnam, Nepal, Mauritius, Syria, and SADC region (via ZaZiBoNa approval)**. - **Eurasia:** EAEU accreditation covers **Russia, Kazakhstan, Armenia, Belarus**. - **Export Growth:** - Grew by **73% YoY (from ₹46 cr to ₹80 cr)** in FY25. - Target: **Triple exports in next 2–3 years**, driven by **64% CAGR (FY20–FY25)**. - **Regulatory Momentum:** - **148+ dossiers submitted**, with **43 new product approvals** in last 6 months. - Planning **150+ dossier filings in next 1.5 years**. - Centralizing regulatory operations at HQ with **6 new hires** to double capacity. --- ### **Regulatory & Quality Accreditations** - **Key Approvals:** - **COFEPRIS (Mexico):** Enables access to **$1.3B oncology market** and allows registration across PICS nations. - **INVIMA (Colombia):** For injectable and oral oncology formulations. - **ANVISA (Brazil), EAEU, ZaZiBoNa, PICS** – validate global quality compliance. - **Upcoming Audits:** - **EU-GMP audit** scheduled for **December 2025/January 2026**, paving way for European market entry. - **First cytotoxic suspension plant globally** to undergo pending European inspection (competitive advantage). --- ### **Recent Strategic Moves & Financials (FY25–FY26)** #### **Capital & Investment** - **Fundraising:** Raised **₹117 crores** in FY25 from marquee investors: - **HealthQuad** (backed by Merck, J&J, and global DFI funds) - **Tanas Capital** (Singapore-based growth fund) - **Use of Funds:** R&D infrastructure, manufacturing expansion, global market access, and API/intermediate integration. #### **Financial Highlights** - **PAT Margin:** **14.10% (ex. one-time interest)**, up from 13.55% YoY. - **FY26 Revenue Guidance:** **> ₹450 crores**, with **EBITDA margins of 23–24%**. - **Long-Term Goal:** Double revenues in 3 years; reach **₹750 crores by FY28**. #### **Ownership & Governance** - **Subsidiaries:** - Adley Formulations Pvt Ltd (Formulations) - Adley Lab Limited (API & Intermediates) - Beta Research Private Limited (R&D) - **Manufacturing Zones:** Baddi (HP), Derabassi (Punjab), with 14-acre land allotted for future API expansion under **Make in India initiative**. --- ### **Key Strengths & Competitive Advantages** 1. **Vertical Integration:** In-house control from KSM → API → Formulation → CDMO. 2. **Cost Leadership:** Backward integration enables **low-cost, high-quality production** with pricing advantage in hospitals. 3. **Regulatory Readiness:** Multiple approvals in **PICS, EU aspirant, LATAM, CIS** markets. 4. **First-Mover Innovation:** Leader in **NDDS, cytotoxic suspensions, and oral oncology**. 5. **Diversified Revenue Streams:** Branded (34%), CDMO (39%), International (21%), with growing API exports. 6. **Strong R&D:** Agile development of **first-to-market products** and complex formulations.